- Home
- BZUN vs CHRS Comparison
BZUN vs CHRS Comparison
Compare BZUN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- CHRS
- Stock Information
- Founded
- BZUN 2007
- CHRS 2010
- Country
- BZUN China
- CHRS United States
- Employees
- BZUN N/A
- CHRS 235
- Industry
- BZUN Catalog/Specialty Distribution
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BZUN Consumer Discretionary
- CHRS Health Care
- Exchange
- BZUN Nasdaq
- CHRS Nasdaq
- Market Cap
- BZUN 188.7M
- CHRS 134.4M
- IPO Year
- BZUN N/A
- CHRS 2014
- Fundamental
- Price
- BZUN $3.18
- CHRS $1.22
- Analyst Decision
- BZUN Strong Buy
- CHRS Strong Buy
- Analyst Count
- BZUN 3
- CHRS 4
- Target Price
- BZUN $3.20
- CHRS $5.38
- AVG Volume (30 Days)
- BZUN 427.0K
- CHRS 2.4M
- Earning Date
- BZUN 03-20-2025
- CHRS 03-12-2025
- Dividend Yield
- BZUN N/A
- CHRS N/A
- EPS Growth
- BZUN N/A
- CHRS N/A
- EPS
- BZUN N/A
- CHRS N/A
- Revenue
- BZUN $1,312,737,613.00
- CHRS $304,340,000.00
- Revenue This Year
- BZUN $8.16
- CHRS $2.47
- Revenue Next Year
- BZUN $4.71
- CHRS N/A
- P/E Ratio
- BZUN N/A
- CHRS N/A
- Revenue Growth
- BZUN 7.26
- CHRS 44.19
- 52 Week Low
- BZUN $2.11
- CHRS $0.66
- 52 Week High
- BZUN $4.38
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- BZUN 55.29
- CHRS 44.03
- Support Level
- BZUN $3.05
- CHRS $1.03
- Resistance Level
- BZUN $3.30
- CHRS $1.23
- Average True Range (ATR)
- BZUN 0.16
- CHRS 0.13
- MACD
- BZUN 0.03
- CHRS -0.02
- Stochastic Oscillator
- BZUN 62.50
- CHRS 38.89
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.